<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-10-22</article-id><article-id pub-id-type="pmid">19265545</article-id><article-id pub-id-type="doi">10.1186/1471-2350-10-22</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Contrasting genetic association of <italic>IL2RA </italic>with SLE and ANCA &#x02013; associated vasculitis</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Carr</surname><given-names>Edward J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ejc58@cam.ac.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Clatworthy</surname><given-names>Menna R</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>mrc38@cam.ac.uk</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Lowe</surname><given-names>Christopher E</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>cl277@medschl.cam.ac.uk</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Todd</surname><given-names>John A</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>john.todd@cimr.cam.ac.uk</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Wong</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>a.wong@nshd.mrc.ac.uk</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Vyse</surname><given-names>Timothy J</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>t.vyse@imperial.ac.uk</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Kamesh</surname><given-names>Lavanya</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>l.kamesh@btinternet.com</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Watts</surname><given-names>Richard A</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>richard.watts@ipswichhospital.nhs.uk</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Lyons</surname><given-names>Paul A</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>pal34@cam.ac.uk</email></contrib><contrib id="A10" corresp="yes" contrib-type="author"><name><surname>Smith</surname><given-names>Kenneth GC</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>kgcs2@cam.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Cambridge Institute for Medical Research, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0XY, UK</aff><aff id="I2"><label>2</label>Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0XY, UK</aff><aff id="I3"><label>3</label>Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0XY, UK</aff><aff id="I4"><label>4</label>Imperial College, Molecular Genetics and Rheumatology Section, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK</aff><aff id="I5"><label>5</label>Division of Infection and Immunity, Medical School, University of Birmingham, Birmingham, B15 2TT, UK</aff><aff id="I6"><label>6</label>School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, NR4 7TJ, UK</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>5</day><month>3</month><year>2009</year></pub-date><volume>10</volume><fpage>22</fpage><lpage>22</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/22"/><history><date date-type="received"><day>4</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>5</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Carr et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Carr et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Carr J Edward ejc58@cam.ac.uk </dc:author><dc:title> Contrasting genetic association of IL2RA with SLE and ANCA &#x02013; associated vasculitis </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 10(1): 22-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2009)10:1&#x0003c;22&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Autoimmune diseases are complex and have genetic and environmental susceptibility factors. The objective was to test the genetic association of systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody (ANCA) &#x02013; associated systemic vasculitis (AAV) with SNPs in the <italic>IL2RA </italic>region and to correlate genotype with serum levels of IL-2RA.</p></sec><sec sec-type="methods"><title>Methods</title><p>Using a cohort of over 700 AAV patients, two SLE case-control studies and an SLE trio collection (totalling over 1000 SLE patients), and a TaqMan genotyping approach, we tested 3 SNPs in the IL2RA locus, rs11594656, rs2104286 &#x00026; rs41295061, each with a prior association with autoimmune disease; rs11594656 and rs41295061 with type 1 diabetes (T1D) and rs2104286 with multiple sclerosis (MS) and T1D.</p></sec><sec><title>Results</title><p>We show that SLE is associated with rs11594656 (<italic>P </italic>= 3.87 &#x000d7; 10<sup>-7</sup>) and there is some evidence of association of rs41295061 with AAV (<italic>P </italic>= 0.0122), which both have prior association with T1D. rs2104286, an MS and T1D &#x02013; associated SNP in the <italic>IL2RA </italic>locus, is not associated with either SLE or AAV.</p></sec><sec><title>Conclusion</title><p>We have confirmed a previous suggestion that the <italic>IL2RA </italic>locus is associated with SLE and showed some evidence of association with AAV. Soluble IL-2RA concentrations correlate with rs11594656 genotype in quiescent disease in both AAV and SLE. Differential association of autoimmune diseases and SNPs within the <italic>IL2RA </italic>locus suggests that the <italic>IL2RA </italic>pathway may prove to play differing, as yet undefined, roles in each disease.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Most autoimmune diseases are polygenic, with genetic susceptibility being conferred by common variants at a number of loci. It is evident that some susceptibility loci are shared between autoimmune diseases. One locus that is associated with several diseases including T1D, MS and Graves' disease, is <italic>IL2RA </italic>[<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>].</p><p>The IL-2 pathway is critical for the maintenance of peripheral tolerance. Activated T cells and regulatory T cells express IL-2RA, the high affinity IL-2 receptor (or CD25). IL-2RA expression has also been reported on activated B cells, activated monocytes, and NK cells [<xref ref-type="bibr" rid="B5">5</xref>]. IL-2 signalling supports the division and survival of effector T cells, plays a role in activation-induced cell death and is vital to regulatory T cell homeostasis [<xref ref-type="bibr" rid="B6">6</xref>]. Its physiological role on other IL-2RA expressing cell types, however, is unclear. One human patient, homozygous for a 4 base pair exonic deletion in <italic>IL2RA</italic>, lacking a functional IL-2RA demonstrated increased susceptibility to viral, bacterial and fungal infections, but unlike <italic>Il2ra</italic>-deficient mice did not develop overt autoimmune disease [<xref ref-type="bibr" rid="B7">7</xref>]. Thus, the IL-2 pathway has a profound effect on the T cell immune response, contributing to both activation and regulation depending on the immunological context.</p><p>In T1D, two disease-associated SNPs [rs11594656 and rs41295061] are required to explain association with this region of chromosome 10p15, indicating that there are multiple functional alleles of the <italic>IL2RA </italic>locus, presumably altering expression of the receptor [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. In addition, associations have been established with multiple sclerosis (MS) [rs2104286] [<xref ref-type="bibr" rid="B3">3</xref>], and suggested with Graves' disease [<xref ref-type="bibr" rid="B4">4</xref>]. The SNP, rs2104286, has also been associated recently with T1D, representing a third independent effect for the <italic>IL2RA </italic>region in this autoimmune disease [<xref ref-type="bibr" rid="B8">8</xref>]. In systemic lupus erythematosus (SLE), SNPs without any prior autoimmune associations [rs7072793, rs4147539, rs7090530 and rs12251307] were examined in a candidate gene analysis of <italic>IL2RA</italic>, providing weak evidence for association [<xref ref-type="bibr" rid="B9">9</xref>]. Soluble IL-2RA (sIL-2RA) is shed from human T cells following <italic>in vitro </italic>activation in response to a variety of polyclonal stimuli [<xref ref-type="bibr" rid="B5">5</xref>]. Significantly elevated serum sIL-2RA has been described in infection, malignancy and in autoimmune disease, including T1D, rheumatoid arthritis, SLE and Wegener's granulomatosis [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B10">10</xref>], although the functional implications of this remain unclear. Genotype at rs11594656 and rs41295061 [<xref ref-type="bibr" rid="B2">2</xref>], and most recently with rs2104286 [<xref ref-type="bibr" rid="B8">8</xref>], has been shown to correlate with serum sIL-2RA concentrations. We therefore genotyped autoimmune disease-prone variants of the <italic>IL2RA </italic>region (rs11594656, rs41595061 and rs2104286) in two distinct autoimmune diseases associated with soluble IL-2RA elevation, using three independent SLE cohorts and one AAV cohort. SLE is a polygenic multi-system disease characterised by immune complex formation and deposition, frequently associated with anti-dsDNA antibodies and complement dysregulation. The clinical features vary between patients, both in severity and system involvement, and include joint, skin, renal and neurological manifestations. AAV can be divided into three clinical syndromes (Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome). All are characterised by inflammation of medium to small calibre blood vessels, and the presence of anti-neutrophil cytoplasmic antibody (ANCA). The clinical presentation of AAV is variable between patients. Severe manifestations include acute glomerulonephritis and granulomatous inflammation of the upper and lower respiratory tract. We also assessed serum titres of sIL-2RA in both diseases.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>AAV</title><p>The AAV cohort (n = 744) comprises subjects from four sources, all meeting the Chapel Hill diagnostic criteria [<xref ref-type="bibr" rid="B11">11</xref>]:</p><p>1. The MRC/Kidney Research UK National DNA Bank for Glomerulonephritis (KRUK-AAV). Individuals were between the ages of 18 and 70 years, were ANCA seropositive, and had biopsy-proven necrotizing glomerulonephritis.</p><p>2. The UK vasculitis cohort 2 was recruited from 9 centres in the UK and comprised patients seropositive for ANCA and/or with histological evidence of small vessel vasculitis.</p><p>3. Patients recruited from the University of Birmingham. All individuals were ANCA seropositive with firm clinical and/or histological evidence of vasculitis.</p><p>4. The Lupus and Vasculitis Service, Addenbrooke's Hospital, Cambridge. All individuals were ANCA seropositive with firm clinical and/or histological evidence of vasculitis.</p></sec><sec><title>SLE</title><p>The KRUK-SLE cohort (n = 220) was obtained from the MRC/Kidney Research UK National DNA Bank for Glomerulonephritis (KRUK) and the Lupus and Vasculitis Service, Addenbrooke's Hospital, Cambridge. All individuals were between the ages of 18 and 50 years with a definite diagnosis of lupus nephritis based on biopsy and on the clinical and serological features defined by the American College of Rheumatology (ACR) [<xref ref-type="bibr" rid="B12">12</xref>]. The Imperial case-control cohort comprised 480 SLE patients and there were 471 trios in the Imperial family cohort (<italic>ie </italic>471 affected sons/daughters, 942 parents) [<xref ref-type="bibr" rid="B13">13</xref>]. Both Imperial cohorts used the ACR defined clinical and serological features. Since the KRUK-SLE cohort used the additional inclusion criterion of biopsy-proven renal involvement, it was analysed separately from the Imperial case-control cohort.</p><p>Genotyping was performed using TaqMan genotyping kits (Applied Biosystems) for each SNP, with fluorescence data captured using an ABI 7900HT (Applied Biosystems) after 40 cycles of PCR.</p></sec><sec><title>Assessment of disease activity</title><p>Birmingham Vasculitis Activity Scores (BVAS) were calculated for AAV patients seen by the Lupus and Vasculitis Service at Addenbrooke's hospital. BVAS assesses both constitutional and organ-specific symptoms, determining whether they are new or pre-existing [<xref ref-type="bibr" rid="B14">14</xref>]. British Isles Lupus Assessment Group (BILAG) scores were used to assess disease activity in SLE patients seen by the Lupus and Vasculitis Service at Addenbrooke's hospital. BILAG scores assess 9 different organ systems based upon a physician's intention to treat [<xref ref-type="bibr" rid="B15">15</xref>]. A flare was defined when three criteria were met: 1. Worsening disease activity scores (at least 1 major or 3 minor BVAS criteria for AAV; a new BILAG score A or B in any system for SLE), 2. clinical impression of active disease and 3. an increase in immunosuppressive treatment.</p></sec><sec><title>Controls</title><p>Control genotypes for 9115 individuals from the British 1958 Birth Cohort and UK Blood Service were obtained from the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory [<xref ref-type="bibr" rid="B16">16</xref>]. This cohort is an expansion of a dataset previously shown to be appropriate for us as UK-wide controls [<xref ref-type="bibr" rid="B17">17</xref>]. The 1958 Birth Cohort DNA was collected as part of an ongoing study following all births in England, Scotland and Wales in one week in 1958 <ext-link ext-link-type="uri" xlink:href="http://www.b58cgene.sgul.ac.uk"/>. For the SLE analysis, controls were split into two groups and one group used as controls for each case cohort: n = 4534 controls for the KRUK cohort and n = 4581 for the Imperial cohort. Some of these control individuals were used in the earlier T1D studies [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>].</p></sec><sec><title>ELISA</title><p>Serum soluble IL-2RA was measured in triplicate using an ELISA, according to the manufacturer's instructions (R&#x00026;D Systems). Serum from both AAV and SLE patients was collected at presentation with a 'flare' (time 0, see Assessment of disease activity section) and three months later (3 months) by the Lupus and Vasculitis Service, Addenbrooke's Hospital, Cambridge.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed using Prism (GraphPad), and R <ext-link ext-link-type="uri" xlink:href="http://www.r-project.org"/>. Case control analyses were performed using &#x003c7;<sup>2 </sup>tests for significance on 2 &#x000d7; 2 contingency tables. Odds ratios and 95% confidence intervals were calculated from the same 2 &#x000d7; 2 tables. The Imperial trio data was analysed using the transmission disequilibrium test (TDT). ELISA data were tested for significance using linear regression modelling or the Mann-Whitney test, as indicated in the figure legends.</p><p>This study was approved by the Cambridge Local Research Ethics Committee and by the Oversight Committee of the KRUK DNA Bank.</p></sec></sec><sec><title>Results</title><p>In all three of our SLE cohorts, rs11594656 was found to be significantly associated with disease (protective minor allele, as seen in T1D), combined <italic>P </italic>= 3.87 &#x000d7; 10<sup>-7 </sup>(KRUK case control <italic>P </italic>= 1 &#x000d7; 10<sup>-4</sup>, Imperial case control <italic>P </italic>= 0.0221 and Imperial family trio TDT <italic>P </italic>= 2.8 &#x000d7; 10<sup>-3</sup>) (Figure <xref ref-type="fig" rid="F1">1</xref> and Table <xref ref-type="table" rid="T1">1</xref>). Neither of the other two SNPs were associated with SLE (Figure <xref ref-type="fig" rid="F1">1</xref> and Table <xref ref-type="table" rid="T1">1</xref>). In AAV, in contrast, some evidence for an association was found with rs41295061 (<italic>P </italic>= 0.0122; minor allele odds ratio = 0.7739; 95% OR CI 0.6330 &#x02013; 0.9461). The minor allele is protective as in T1D. However, neither rs2104286 or rs11594656 showed any association with AAV (Figure <xref ref-type="fig" rid="F1">1</xref> and Table <xref ref-type="table" rid="T1">1</xref>). At 80% power, we can detect effect sizes larger than 1.25 for rs11594656 in AAV and 1.4 for rs41295061 in SLE, across all the SLE cases and controls.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>SLE and AAV are associated with different SNPs in the <italic>IL2RA </italic>region</bold>. The genomic context of rs2104286, rs41295061 and rs11594656 is shown, using the GBrowse implementation in T1DBase <ext-link ext-link-type="uri" xlink:href="http://www.t1dbase.org"/>. All are non-coding SNPs. Negative decimal logarithms of <italic>P </italic>values (&#x003c7;<sup>2 </sup>test; 1 degree of freedom) from each cohort from SLE and AAV are plotted for rs41295061 and rs11594656 but not for rs2104286, as an association of this MS-associated SNP was not detected with SLE or AAV (table 1). Open circles represent the KRUK case-control cohort; filled circles the Imperial case-control cohort and open squares the Imperial family trios (<italic>P </italic>value from TDT). The filled square represents the combined <italic>P </italic>value for rs11594656 in SLE. Crosses are used for the AAV cohort. The dashed lines correspond to <italic>P = </italic>0.05.</p></caption><graphic xlink:href="1471-2350-10-22-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Genotype data at rs11594656, rs41295061 and rs2104286 for SLE and AAV</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="3">SLE</td><td align="left">AAV</td></tr><tr><td></td><td align="left">KRUK cases</td><td align="left">Imperial cases</td><td align="left">Imperial trios</td><td></td></tr></thead><tbody><tr><td align="left"><bold>rs11594656 T&#x0003e;A</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Genotyped cases</td><td align="left">208</td><td align="left">441</td><td align="left">481</td><td align="left">670</td></tr><tr><td align="left">TT, TA, AA</td><td align="left">148, 52, 8</td><td align="left">276, 145, 20</td><td></td><td align="left">382, 252, 36</td></tr><tr><td align="left">Genotyped controls</td><td align="left">4401</td><td align="left">4449</td><td align="left">310 *</td><td align="left">8850</td></tr><tr><td align="left">TT, TA, AA</td><td align="left">2486, 1655, 260</td><td align="left">2542, 1640, 267</td><td></td><td align="left">5028, 3295, 527</td></tr><tr><td align="left">MAF in cases</td><td align="left">0.16</td><td align="left">0.20</td><td align="left">-</td><td align="left">0.24</td></tr><tr><td align="left"><italic>P </italic>value (1 d.f. test)</td><td align="left">1 &#x000d7; 10<sup>-4</sup></td><td align="left">0.0221</td><td align="left">2.8 &#x000d7; 10<sup>-3</sup></td><td align="left">0.7481</td></tr><tr><td align="left">OR for minor allele</td><td align="left">0.595</td><td align="left">0.82</td><td align="left">-</td><td align="left">1.02</td></tr><tr><td align="left">95% CI for OR</td><td align="left">0.4570 &#x02013; 0.7756</td><td align="left">0.6931 &#x02013; 0.9723</td><td align="left">-</td><td align="left">0.8972 &#x02013; 1.163</td></tr><tr><td align="left"><bold>rs41295061 C&#x0003e;A</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Genotyped cases</td><td align="left">208</td><td align="left">421</td><td align="left">471</td><td align="left">675</td></tr><tr><td align="left">CC, CA, AA</td><td align="left">172, 33, 3</td><td align="left">330, 80, 11</td><td></td><td align="left">569, 102, 4</td></tr><tr><td align="left">Genotyped controls</td><td align="left">4438</td><td align="left">4498</td><td align="left">137 *</td><td align="left">8936</td></tr><tr><td align="left">CC, CA, AA</td><td align="left">3603, 790, 45</td><td align="left">3603, 832, 63</td><td></td><td align="left">7206, 1622, 108</td></tr><tr><td align="left">MAF in cases</td><td align="left">0.09</td><td align="left">0.12</td><td align="left">-</td><td align="left">0.08</td></tr><tr><td align="left"><italic>P </italic>value (1 d.f. test)</td><td align="left">0.7187</td><td align="left">0.1899</td><td align="left">0.2000</td><td align="left">0.0122</td></tr><tr><td align="left">OR for minor allele</td><td align="left">0.94</td><td align="left">1.154</td><td align="left">-</td><td align="left">0.7739</td></tr><tr><td align="left">95% CI for OR</td><td align="left">0.6710 &#x02013; 1.317</td><td align="left">0.9307 &#x02013; 1.438</td><td align="left">-</td><td align="left">0.6330 &#x02013; 0.9461</td></tr><tr><td align="left"><bold>rs2104286 A&#x0003e;G</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Genotyped cases</td><td align="left">198</td><td align="left">436</td><td align="left">471</td><td align="left">380</td></tr><tr><td align="left">AA, AG, GG</td><td align="left">113, 74, 11</td><td align="left">234, 158, 44</td><td></td><td align="left">207, 148, 25</td></tr><tr><td align="left">Genotyped controls</td><td align="left">3475</td><td align="left">3529</td><td align="left">353 *</td><td align="left">7004</td></tr><tr><td align="left">AA, AG, GG</td><td align="left">1823, 1403, 249</td><td align="left">1825, 1452, 252</td><td></td><td align="left">3648, 2855, 501</td></tr><tr><td align="left">MAF in cases</td><td align="left">0.24</td><td align="left">0.28</td><td align="left">-</td><td align="left">0.26</td></tr><tr><td align="left"><italic>P </italic>value (1 d.f. test)</td><td align="left">0.1760</td><td align="left">0.7568</td><td align="left">0.558</td><td align="left">0.3727</td></tr><tr><td align="left">OR for minor allele</td><td align="left">1.177</td><td align="left">0.9756</td><td align="left">-</td><td align="left">1.078</td></tr><tr><td align="left">95% CI for OR</td><td align="left">0.9294 &#x02013; 1.490</td><td align="left">0.8343 &#x02013; 1.141</td><td align="left">-</td><td align="left">0.9133 &#x02013; 1.273</td></tr></tbody></table><table-wrap-foot><p>MAF minor allele frequency; OR odds ratio; CI confidence interval; * informative transmissions. Genotype frequencies are shown for the case control cohorts.</p></table-wrap-foot></table-wrap><p>In both SLE and AAV, sIL-2RA concentrations were significantly higher than controls (Figure <xref ref-type="fig" rid="F2">2a</xref>). In SLE, disease activity as assessed by BILAG score did not show a significant correlation with sIL-2RA concentrations (Figure <xref ref-type="fig" rid="F2">2b</xref>), despite previous reports of a correlation between sIL-2RA concentrations and disease activity [<xref ref-type="bibr" rid="B5">5</xref>]. However, in AAV, disease activity as assessed by BVAS showed a positive correlation with sIL-2RA concentration (Figure <xref ref-type="fig" rid="F2">2c</xref>, [<xref ref-type="bibr" rid="B10">10</xref>]). Three months after commencement of treatment, when both diseases were considerably less active (mean BILAG decreased from 16.1 to 4.7 and mean BVAS from 13.9 to 4.4), sIL-2RA concentrations correlated with the SLE associated rs11594656 genotype (Figures <xref ref-type="fig" rid="F2">2d</xref> &#x00026;<xref ref-type="fig" rid="F2">2e</xref>). In active AAV this correlation no longer held true (figure <xref ref-type="fig" rid="F2">2e</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Serum soluble IL-2RA in SLE and AAV and its relationship with disease activity and genotype at rs11594656</bold>. (a) A comparison of SLE and AAV soluble IL-2RA (sIL-2RA) at time 0 and 3 months compared with controls, as assessed by ELISA. Each dot represents a patient. (b, c) Correlation between disease activity and sIL-2RA. (BILAG for SLE; BVAS for AAV; see supplementary information). r<sup>2 </sup>and <italic>P </italic>values from linear regression modelling are shown. (d, e) sIL-2RA levels stratified by genotype at rs11594656 at both time 0 and 3 months for SLE (d) and AAV (e). <italic>P </italic>values for panels (a), (d) &#x00026; (e) were generated using the Mann-Whitney test.</p></caption><graphic xlink:href="1471-2350-10-22-2"/></fig></sec><sec><title>Discussion</title><p>We have shown a novel <italic>IL2RA </italic>association with AAV and confirm the <italic>IL2RA </italic>locus association with SLE. This brings the number of autoimmune diseases associated with this gene to five, the others being T1D, MS and Graves' disease [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. An association of SLE with <italic>IL2RA </italic>(rs7072793, <italic>P </italic>= 0.01) was generated by candidate gene re-analysis of genome-wide association data from 720 female patients [<xref ref-type="bibr" rid="B9">9</xref>]. The present study uses 1130 SLE genotypes, of mixed gender, in three independent cohorts, and demonstrates a strong association with the <italic>IL2RA </italic>region (rs11594656, <italic>P </italic>= 3.87 &#x000d7; 10<sup>-7</sup>). Owing to strong co-segregation of these disorders in cases and families, susceptibility loci can be shared across different autoimmune diseases. Several examples at the gene-specific level are known, including <italic>CTLA-4 </italic>[<xref ref-type="bibr" rid="B18">18</xref>] and <italic>PTPN22 </italic>[<xref ref-type="bibr" rid="B19">19</xref>]. Our study underlines that this sharing can occur at the single gene level for <italic>IL2RA </italic>for T1D and SLE, two diseases in which co-segregation is less well recognised.</p><p>Our findings demonstrate that the association between <italic>IL2RA </italic>and autoimmune disease is not a simple one. SLE is associated with rs11594656, but not rs41295061 and in AAV there is some evidence for an association with rs41295061 but not with rs11594656. Moreover, in T1D, all three SNPs are associated with disease, but the strength of association varies with each (rs41295061, <italic>P = </italic>6.43 &#x000d7; 10<sup>-25</sup>; rs2104286, <italic>P </italic>= 1.27 &#x000d7; 10<sup>-13</sup>; rs11594656, <italic>P </italic>= <italic>3</italic>.37 &#x000d7; 10<sup>-6</sup>) [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. In MS, whilst rs2104286 is associated with disease [<xref ref-type="bibr" rid="B3">3</xref>], rs11594656 or rs41295061 are not (rs11594656, <italic>P </italic>= 0.293; rs41295061, <italic>P </italic>= 0.625) [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>There are differences at the functional level as well, with rs11594656 genotype correlated with sIL-2RA levels in both SLE and AAV despite only having genetic association with SLE. This correlation is present in both SLE and AAV three months following disease flare, but absent at the time of flare itself, perhaps because local inflammatory mechanisms provide a major contribution to sIL-2RA, overriding the influence of genotype. Thus the degree of autoimmune disease activity needs to be taken into account in studies attempting to correlate genotype with markers such as sIL-2RA.</p><p>There is precedent for such contrasting functional and genetic associations between SLE and AAV. Fc&#x003b3;RIIIb, a neutrophil-specific low affinity activatory Fc receptor, has two allotypic variants, which have a significant effect on the affinity of the receptor for IgG. One of these, <italic>FCGR3B*NA1</italic>, is associated with SLE, and the other, <italic>FCGR3B*NA2</italic>, with AAV [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Moreover, copy number at <italic>FCGR3B </italic>is associated with expression and function of the receptor [<xref ref-type="bibr" rid="B22">22</xref>], and low copy number is associated with SLE [<xref ref-type="bibr" rid="B23">23</xref>] but not with AAV ([<xref ref-type="bibr" rid="B22">22</xref>] &#x00026; data not shown). The association of a single gene with different diseases indicates the importance in disease of the biological pathway subserved by that gene, but it does not imply that defects in the gene lead to a similar functional perturbation in each case. Thus the same gene, <italic>IL2RA</italic>, is associated with both SLE and AAV, but may play quite distinct roles in these diseases.</p></sec><sec><title>Conclusion</title><p>We confirm the association of the <italic>IL2RA </italic>locus with SLE, by genotyping rs11594656 across three independent cohorts, using two different study designs. We report evidence for a novel association of the <italic>IL2RA </italic>locus with AAV. The MS-associated SNP, rs2104286, is not associated with either disease in our cohorts. Soluble IL-2RA concentrations were elevated in SLE and AAV. After three months of treatment, soluble IL-2RA concentrations in both diseases correlated with the SLE associated rs11594656 genotype. The contrasting genetic and functional associations found between SLE and AAV and the <italic>IL2RA </italic>locus presumably reflect differences in disease pathogenesis.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>KGCS and PAL conceived and designed the study. AW, TJV, JAT, KL &#x00026; RAW provided access to DNA samples, and TJV &#x00026; JAT assisted in data interpretation. EJC performed the SNP genotyping and its analysis. Additional genotyping and experimental oversight was provided by CEL. MRC contributed the ELISA data and its analysis. The manuscript was written by EJC &#x00026; KGCS. Additionally, MRC, CEL, TJV, PAL &#x00026; JAT actively contributed to discussion of the results of this manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/22/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We acknowledge the participation of all of the patients, control subjects and family members. We acknowledge use of DNA from the MRC/Kidney Research UK National DNA Bank for Glomerulonephritis and Neil Walker for his curation and supply of data from the British 1958 Birth Cohort. We thank Jane Hollis and Kirsty Townsend for serum sample collections, David Jayne and Afzal Chaudry for their clinical input, and Caroline Savage, Lorraine Harper and Dwomoa Adu for contributions to DNA collections.</p><p>This work was funded by the NIHR Cambridge Biomedical Research Centre, the Medical Research Council (MRC), the Wellcome Trust (Programme Grant Number 083650/Z/07/Z), and a combined Wellcome Trust &#x02013; Juvenile Diabetes Research Foundation grant. The Cambridge Institute for Medical Research is in receipt of a Wellcome Trust Strategic Award (079895). EJC was funded by a MRC Doctoral Training Account studentship.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vella</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>JD</given-names></name><name><surname>Lowe</surname><given-names>CE</given-names></name><name><surname>Walker</surname><given-names>N</given-names></name><name><surname>Nutland</surname><given-names>S</given-names></name><name><surname>Widmer</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Ring</surname><given-names>SM</given-names></name><name><surname>McArdle</surname><given-names>W</given-names></name><name><surname>Pembrey</surname><given-names>ME</given-names></name><name><surname>Strachan</surname><given-names>D</given-names></name><name><surname>Dunger</surname><given-names>DB</given-names></name><name><surname>Twells</surname><given-names>RC</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name></person-group><article-title>Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms</article-title><source>Am J Hum Genet</source><year>2005</year><volume>76</volume><fpage>773</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">15776395</pub-id><pub-id pub-id-type="doi">10.1086/429843</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>CE</given-names></name><name><surname>Cooper</surname><given-names>JD</given-names></name><name><surname>Brusko</surname><given-names>T</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Smyth</surname><given-names>DJ</given-names></name><name><surname>Bailey</surname><given-names>R</given-names></name><name><surname>Bourget</surname><given-names>K</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Field</surname><given-names>S</given-names></name><name><surname>Atkinson</surname><given-names>M</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Wicker</surname><given-names>LS</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name></person-group><article-title>Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>1074</fpage><lpage>1082</lpage><pub-id pub-id-type="pmid">17676041</pub-id><pub-id pub-id-type="doi">10.1038/ng2102</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><collab>International Multiple Sclerosis Genetics Consortium</collab></person-group><article-title>Risk alleles for multiple sclerosis identified by a genomewide study</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>851</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">17660530</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa073493</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>OJ</given-names></name><name><surname>Lowe</surname><given-names>CE</given-names></name><name><surname>Heward</surname><given-names>JM</given-names></name><name><surname>Franklyn</surname><given-names>JA</given-names></name><name><surname>Cooper</surname><given-names>JD</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Gough</surname><given-names>SC</given-names></name></person-group><article-title>Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs</article-title><source>Clin Endocrinol (Oxf)</source><year>2007</year><volume>66</volume><fpage>508</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">17371467</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>C</given-names></name><name><surname>Candore</surname><given-names>G</given-names></name><name><surname>Cigna</surname><given-names>D</given-names></name><name><surname>Colucci</surname><given-names>AT</given-names></name><name><surname>Modica</surname><given-names>MA</given-names></name></person-group><article-title>Biological significance of soluble IL-2 receptor</article-title><source>Mediators Inflamm</source><year>1993</year><volume>2</volume><fpage>3</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">18475497</pub-id><pub-id pub-id-type="doi">10.1155/S0962935193000018</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malek</surname><given-names>TR</given-names></name></person-group><article-title>The biology of interleukin-2</article-title><source>Annu Rev Immunol</source><year>2008</year><volume>26</volume><fpage>453</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">18062768</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090357</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharfe</surname><given-names>N</given-names></name><name><surname>Dadi</surname><given-names>HK</given-names></name><name><surname>Shahar</surname><given-names>M</given-names></name><name><surname>Roifman</surname><given-names>CM</given-names></name></person-group><article-title>Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>3168</fpage><lpage>3171</lpage><pub-id pub-id-type="pmid">9096364</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.7.3168</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>LM</given-names></name><name><surname>Lowe</surname><given-names>CE</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>DE</given-names></name><name><surname>Severson</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>PM</given-names></name><name><surname>Healy</surname><given-names>B</given-names></name><name><surname>Walker</surname><given-names>N</given-names></name><name><surname>Aubin</surname><given-names>C</given-names></name><name><surname>Oksenberg</surname><given-names>JR</given-names></name><name><surname>Hauser</surname><given-names>SL</given-names></name><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Sawcer</surname><given-names>S</given-names></name><name><surname>Consortium</surname><given-names>TIMSG</given-names></name><name><surname>Jager</surname><given-names>PLD</given-names></name><name><surname>Wicker</surname><given-names>LS</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><article-title>IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production</article-title><source>PLoS Genet</source><year>2009</year><volume>5</volume><fpage>e1000322</fpage><pub-id pub-id-type="pmid">19119414</pub-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000322</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><collab>The International Consortium for Systemic Lupus Erythematosus Genetics</collab></person-group><article-title>Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">18204446</pub-id><pub-id pub-id-type="doi">10.1038/ng.81</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>WH</given-names></name><name><surname>Heesen</surname><given-names>C</given-names></name><name><surname>Csernok</surname><given-names>E</given-names></name><name><surname>Rautmann</surname><given-names>A</given-names></name><name><surname>Gross</surname><given-names>WL</given-names></name></person-group><article-title>Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity</article-title><source>Arthritis Rheum</source><year>1992</year><volume>35</volume><fpage>1088</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">1418025</pub-id><pub-id pub-id-type="doi">10.1002/art.1780350914</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jennette</surname><given-names>JC</given-names></name><name><surname>Falk</surname><given-names>RJ</given-names></name><name><surname>Andrassy</surname><given-names>K</given-names></name><name><surname>Bacon</surname><given-names>PA</given-names></name><name><surname>Churg</surname><given-names>J</given-names></name><name><surname>Gross</surname><given-names>WL</given-names></name><name><surname>Hagen</surname><given-names>EC</given-names></name><name><surname>Hoffman</surname><given-names>GS</given-names></name><name><surname>Hunder</surname><given-names>GG</given-names></name><name><surname>Kallenberg</surname><given-names>CGM</given-names></name><name><surname>Mccluskey</surname><given-names>RT</given-names></name><name><surname>Sinico</surname><given-names>RA</given-names></name><name><surname>Rees</surname><given-names>AJ</given-names></name><name><surname>Van Es</surname><given-names>LA</given-names></name><name><surname>Waldherr</surname><given-names>R</given-names></name><name><surname>Wiik</surname><given-names>A</given-names></name></person-group><article-title>Nomenclature of Systemic Vasculitides</article-title><source>Arthritis Rheum</source><year>1994</year><volume>37</volume><fpage>187</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">8129773</pub-id><pub-id pub-id-type="doi">10.1002/art.1780370206</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group><article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title><source>Arthritis Rheum</source><year>1997</year><volume>40</volume><fpage>1725</fpage><pub-id pub-id-type="pmid">9324032</pub-id><pub-id pub-id-type="doi">10.1002/art.1780400928</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>DS</given-names></name><name><surname>Graham</surname><given-names>RR</given-names></name><name><surname>Manku</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>AK</given-names></name><name><surname>Whittaker</surname><given-names>JC</given-names></name><name><surname>Gaffney</surname><given-names>PM</given-names></name><name><surname>Moser</surname><given-names>KL</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name><name><surname>Vyse</surname><given-names>TJ</given-names></name></person-group><article-title>Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">18059267</pub-id><pub-id pub-id-type="doi">10.1038/ng.2007.47</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>JH</given-names></name><name><surname>Hoffman</surname><given-names>GS</given-names></name><name><surname>Merkel</surname><given-names>PA</given-names></name><name><surname>Min</surname><given-names>YI</given-names></name><name><surname>Uhlfelder</surname><given-names>ML</given-names></name><name><surname>Hellmann</surname><given-names>DB</given-names></name><name><surname>Specks</surname><given-names>U</given-names></name><name><surname>Allen</surname><given-names>NB</given-names></name><name><surname>Davis</surname><given-names>JC</given-names></name><name><surname>Spiera</surname><given-names>RF</given-names></name><name><surname>Calabrese</surname><given-names>LH</given-names></name><name><surname>Wigley</surname><given-names>FM</given-names></name><name><surname>Maiden</surname><given-names>N</given-names></name><name><surname>Valente</surname><given-names>RM</given-names></name><name><surname>Niles</surname><given-names>JL</given-names></name><name><surname>Fye</surname><given-names>KH</given-names></name><name><surname>McCune</surname><given-names>JW</given-names></name><name><surname>St Clair</surname><given-names>EW</given-names></name><name><surname>Luqmani</surname><given-names>RA</given-names></name></person-group><article-title>A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)</article-title><source>Arthritis Rheum</source><year>2001</year><volume>44</volume><fpage>912</fpage><lpage>920</lpage><pub-id pub-id-type="pmid">11318006</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(200104)44:4&#x0003c;912::AID-ANR148&#x0003e;3.0.CO;2-5</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isenberg</surname><given-names>DA</given-names></name><name><surname>Rahman</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>E</given-names></name><name><surname>Farewell</surname><given-names>V</given-names></name><name><surname>Akil</surname><given-names>M</given-names></name><name><surname>Bruce</surname><given-names>IN</given-names></name><name><surname>D'Cruz</surname><given-names>D</given-names></name><name><surname>Griffiths</surname><given-names>B</given-names></name><name><surname>Khamashta</surname><given-names>M</given-names></name><name><surname>Maddison</surname><given-names>P</given-names></name><name><surname>McHugh</surname><given-names>N</given-names></name><name><surname>Snaith</surname><given-names>M</given-names></name><name><surname>Teh</surname><given-names>LS</given-names></name><name><surname>Yee</surname><given-names>CS</given-names></name><name><surname>Zoma</surname><given-names>A</given-names></name><name><surname>Gordon</surname><given-names>C</given-names></name></person-group><article-title>BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus</article-title><source>Rheumatology (Oxford)</source><year>2005</year><volume>44</volume><fpage>902</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">15814577</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/keh624</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Cooper</surname><given-names>JD</given-names></name><name><surname>Smyth</surname><given-names>DJ</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Bailey</surname><given-names>R</given-names></name><name><surname>Nejentsev</surname><given-names>S</given-names></name><name><surname>Field</surname><given-names>SF</given-names></name><name><surname>Payne</surname><given-names>F</given-names></name><name><surname>Lowe</surname><given-names>CE</given-names></name><name><surname>Szeszko</surname><given-names>JS</given-names></name><name><surname>Hafler</surname><given-names>JP</given-names></name><name><surname>Zeitels</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>JH</given-names></name><name><surname>Vella</surname><given-names>A</given-names></name><name><surname>Nutland</surname><given-names>S</given-names></name><name><surname>Stevens</surname><given-names>HE</given-names></name><name><surname>Schuilenburg</surname><given-names>H</given-names></name><name><surname>Coleman</surname><given-names>G</given-names></name><name><surname>Maisuria</surname><given-names>M</given-names></name><name><surname>Meadows</surname><given-names>W</given-names></name><name><surname>Smink</surname><given-names>LJ</given-names></name><name><surname>Healy</surname><given-names>B</given-names></name><name><surname>Burren</surname><given-names>OS</given-names></name><name><surname>Lam</surname><given-names>AA</given-names></name><name><surname>Ovington</surname><given-names>NR</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Adlem</surname><given-names>E</given-names></name><name><surname>Leung</surname><given-names>HT</given-names></name><etal></etal></person-group><article-title>Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>857</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">17554260</pub-id><pub-id pub-id-type="doi">10.1038/ng2068</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><collab>Wellcome Trust Case Control Consortium</collab></person-group><article-title>Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>661</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">17554300</pub-id><pub-id pub-id-type="doi">10.1038/nature05911</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>H</given-names></name><name><surname>Howson</surname><given-names>JM</given-names></name><name><surname>Esposito</surname><given-names>L</given-names></name><name><surname>Heward</surname><given-names>J</given-names></name><name><surname>Snook</surname><given-names>H</given-names></name><name><surname>Chamberlain</surname><given-names>G</given-names></name><name><surname>Rainbow</surname><given-names>DB</given-names></name><name><surname>Hunter</surname><given-names>KM</given-names></name><name><surname>Smith</surname><given-names>AN</given-names></name><name><surname>Di Genova</surname><given-names>G</given-names></name><name><surname>Herr</surname><given-names>MH</given-names></name><name><surname>Dahlman</surname><given-names>I</given-names></name><name><surname>Payne</surname><given-names>F</given-names></name><name><surname>Smyth</surname><given-names>D</given-names></name><name><surname>Lowe</surname><given-names>C</given-names></name><name><surname>Twells</surname><given-names>RC</given-names></name><name><surname>Howlett</surname><given-names>S</given-names></name><name><surname>Healy</surname><given-names>B</given-names></name><name><surname>Nutland</surname><given-names>S</given-names></name><name><surname>Rance</surname><given-names>HE</given-names></name><name><surname>Everett</surname><given-names>V</given-names></name><name><surname>Smink</surname><given-names>LJ</given-names></name><name><surname>Lam</surname><given-names>AC</given-names></name><name><surname>Cordell</surname><given-names>HJ</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Bordin</surname><given-names>C</given-names></name><name><surname>Hulme</surname><given-names>J</given-names></name><name><surname>Motzo</surname><given-names>C</given-names></name><name><surname>Cucca</surname><given-names>F</given-names></name><name><surname>Hess</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease</article-title><source>Nature</source><year>2003</year><volume>423</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">12724780</pub-id><pub-id pub-id-type="doi">10.1038/nature01621</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vang</surname><given-names>T</given-names></name><name><surname>Miletic</surname><given-names>AV</given-names></name><name><surname>Arimura</surname><given-names>Y</given-names></name><name><surname>Tautz</surname><given-names>L</given-names></name><name><surname>Rickert</surname><given-names>RC</given-names></name><name><surname>Mustelin</surname><given-names>T</given-names></name></person-group><article-title>Protein Tyrosine Phosphatases in Autoimmunity</article-title><source>Annual Review of Immunology</source><year>2008</year><volume>26</volume><fpage>29</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">18303998</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090418</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Edberg</surname><given-names>JC</given-names></name><name><surname>Chatham</surname><given-names>W</given-names></name><name><surname>Fassina</surname><given-names>G</given-names></name><name><surname>Kimberly</surname><given-names>RP</given-names></name></person-group><article-title>Fc gamma RIIIb allele-sensitive release of alpha-defensins: anti-neutrophil cytoplasmic antibody-induced release of chemotaxins</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>6090</fpage><lpage>6096</lpage><pub-id pub-id-type="pmid">14634123</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siriboonrit</surname><given-names>U</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Sirikong</surname><given-names>M</given-names></name><name><surname>Kyogoku</surname><given-names>C</given-names></name><name><surname>Bejrachandra</surname><given-names>S</given-names></name><name><surname>Suthipinittharm</surname><given-names>P</given-names></name><name><surname>Luangtrakool</surname><given-names>K</given-names></name><name><surname>Srinak</surname><given-names>D</given-names></name><name><surname>Thongpradit</surname><given-names>R</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Chandanayingyong</surname><given-names>D</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name></person-group><article-title>Association of Fcgamma receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais</article-title><source>Tissue Antigens</source><year>2003</year><volume>61</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">12753656</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.2003.00047.x</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willcocks</surname><given-names>LC</given-names></name><name><surname>Lyons</surname><given-names>PA</given-names></name><name><surname>Clatworthy</surname><given-names>MR</given-names></name><name><surname>Robinson</surname><given-names>JI</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Newland</surname><given-names>SA</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>McGovern</surname><given-names>NN</given-names></name><name><surname>Condliffe</surname><given-names>AM</given-names></name><name><surname>Chilvers</surname><given-names>ER</given-names></name><name><surname>Adu</surname><given-names>D</given-names></name><name><surname>Jolly</surname><given-names>EC</given-names></name><name><surname>Watts</surname><given-names>R</given-names></name><name><surname>Lau</surname><given-names>YL</given-names></name><name><surname>Morgan</surname><given-names>AW</given-names></name><name><surname>Nash</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>KGC</given-names></name></person-group><article-title>Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>1573</fpage><lpage>1582</lpage><pub-id pub-id-type="pmid">18559452</pub-id><pub-id pub-id-type="doi">10.1084/jem.20072413</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fanciulli</surname><given-names>M</given-names></name><name><surname>Norsworthy</surname><given-names>PJ</given-names></name><name><surname>Petretto</surname><given-names>E</given-names></name><name><surname>Dong</surname><given-names>R</given-names></name><name><surname>Harper</surname><given-names>L</given-names></name><name><surname>Kamesh</surname><given-names>L</given-names></name><name><surname>Heward</surname><given-names>JM</given-names></name><name><surname>Gough</surname><given-names>SCL</given-names></name><name><surname>de Smith</surname><given-names>A</given-names></name><name><surname>Blakemore</surname><given-names>AIF</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Owen</surname><given-names>CJ</given-names></name><name><surname>Pearce</surname><given-names>SHS</given-names></name><name><surname>Teixeira</surname><given-names>L</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name><name><surname>Graham</surname><given-names>DSC</given-names></name><name><surname>Pusey</surname><given-names>CD</given-names></name><name><surname>Cook</surname><given-names>HT</given-names></name><name><surname>Vyse</surname><given-names>TJ</given-names></name><name><surname>Aitman</surname><given-names>TJ</given-names></name></person-group><article-title>FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>721</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">17529978</pub-id><pub-id pub-id-type="doi">10.1038/ng2046</pub-id></citation></ref></ref-list></back></article> 